


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	6.69
Trade Time:	4:00 PM ET Sep 25, 2017
Change:	0.14  (+2.137%)
Day Range	6.44 - 6.90
52-Week Range	1.51 - 8.84
Volume	2,932,727

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.

ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR α -positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyca[®], in other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, B... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 5, 2017
[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

Sep 1, 2017
[ImmunoGen Announces Agreements to Exchange \\$76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock](#)

Aug 29, 2017
[Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products](#)

Aug 1, 2017
[ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference](#)

Jul 28, 2017
[ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Aug 25, 2016
[Annual Report \(10-K\)](#)

Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)

Nov 4, 2016
[Quarterly Report \(10-Q\)](#)